Online inquiry

IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15228MR)

This product GTTS-WQ15228MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15228MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1962MR IVTScrip™ mRNA-Anti-SLITRK6, AGS-15E(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-15E
GTTS-WQ10359MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2062430
GTTS-WQ4628MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ3260MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ7699MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GEXMab73
GTTS-WQ4511MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ9236MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ845MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW